Deal Watch: Genentech Out-Licenses PI3K Inhibitor To Novogen
Executive Summary
The Australian firm also buys out Glioblast to add to its capabilities in brain cancer. Meanwhile, India’s Sun Pharmaceutical acquires Auven’s Ocular Technologies, and GlaxoSmithKline partners with Fimbrion in urinary tract infections and with Zai Lab in autoimmune disorders.
You may also be interested in...
Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
Finance Watch: Two More US Biopharma IPOs And Two New European VC Funds
Two biopharma IPOs in the US continue streak of (mostly) positive returns; two new European VC funds launch as Irish antibiotic developer raises $65m; and Halozyme, Ziopharm price offerings.
Deal Watch: Bristol Leaves Neuropathic Pain Candidate To Lexicon
Verastem steps in where AbbVie exited, agreeing to license Infinity’s duvelisib in hematologic cancer indications. Celldex grows its immuno-oncology pipeline with buyout of private Yale Medical School-spinout Kolltan.
Need a specific report? 1000+ reports available
Buy Reports